Cited by 392interferon and immune responsesSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome

Open access

Cameron, Mark J., Ran, Longsi, Xu, Luoling, Danesh, Ali, Bermejo-Martin, Jesus F., Cameron, Cheryl M., Muller, Matthew P., Gold, Wayne L., Richardson, Susan E., Poutanen, Susan M., Willey, Barbara M., DeVries, Mark E., Fang, Yuan, Seneviratne, Charit, Bosinger, Steven E., Persad, Desmond, Wilkinson, Peter, Greller, Larry D., Somogyi, Roland, Humar, Atul, Keshavjee, Shaf, Louie, Marie, Loeb, Mark B., Brunton, James, McGeer, Allison J., the Canadian SARS Research Network, Kelvin, David J.·2007·Journal of Virology

DOI 10.1128/jvi.00527-07PMC PMC1951379

Open this paper in CoChat — free account

Abstract

It is not understood how immune inflammation influences the pathogenesis of severe acute respiratory syndrome (SARS). One area of strong controversy is the role of interferon (IFN) responses in the natural history of SARS. The fact that the majority of SARS patients recover after relatively moderate illness suggests that the prevailing notion of deficient type I IFN-mediated immunity, with hypercytokinemia driving a poor clinical course, is oversimplified. We used proteomic and genomic technology to systematically analyze host innate and adaptive immune responses of 40 clinically well-described patients with SARS during discrete phases of illness from the onset of symptoms to discharge or a fatal outcome. A novel signature of high IFN-α, IFN-γ, and IFN-stimulated chemokine levels, plus robust antiviral IFN-stimulated gene (ISG) expression, accompanied early SARS sequelae. As acute illness progressed, SARS patients entered a crisis phase linked to oxygen saturation profiles. The majority of SARS patients resolved IFN responses at crisis and expressed adaptive immune genes. In contrast, patients with poor outcomes showed deviated ISG and immunoglobulin gene expression levels, persistent chemokine levels, and deficient anti-SARS spike antibody production. We contend that unregulated IFN responses during acute-phase SARS may culminate in a malfunction of the switch from innate immunity to adaptive immunity. The potential for the use of the gene signatures we describe in this study to better assess the immunopathology and clinical management of severe viral infections, such as SARS and avian influenza (H5N1), is therefore worth careful examination.

Integrity signals

Registry

Crossref · 10.1128/jvi.00527-07

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study
Peiris, J., Chu, C., Cheng, V., Chan, K., Hung, I., Poon, L., Law, K., Tang, B., Hon, T., Chan, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13412-5 · Cited by 2,375
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements
MAQC Consortium, Shi, L., Shi, L., Reid, L. H., Jones, W. D., Shippy, R., Warrington, J. A., Baker, S. C., Collins, P. J., de Longueville, F., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1239 · Cited by 2,126
Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.
de Jong, M. D., Simmons, C. P., Thanh, T. T., Hien, V. M., Smith, G. J. D., Chau, T. N. B., Hoang, D. M., Van Vinh Chau, N., Khanh, T. H., Dong, V. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1477 · Cited by 1,858
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
Wong, C. K., LAM, C. W. K., Wu, A. K. L., Ip, W., Lee, N. L. S., Chan, I., Lit, L. C. W., Hui, D. S. C., Chan, M. H. M., CHUNG, S. S. C., et al. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02415.x · Cited by 1,270
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217

Flagged first, then by citations

Show all 59 references

Sorted by citations

Items 201–300 of 392

Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and “New Old Friends”
Kleen, T. O., Galdon, A. A., MacDonald, A. S., & Dalgleish, A. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02059 · Cited by 29
Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases
Bhattacharya, S., Agarwal, S., Shrimali, N. M., & Guchhait, P. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101000 · Cited by 33
Immune phenotypes that are associated with subsequent COVID-19 severity inferred from post-recovery samples
Liechti, T., Iftikhar, Y., Mangino, M., Beddall, M. H., Goss, C. W., O’Halloran, J. A., Mudd, P. A., & Roederer, M. (2022) · Nature Communications · doi:10.1038/s41467-022-34638-2 · Cited by 32
Two distinct immunopathological profiles in autopsy lungs of COVID-19Preprint
Nienhold, R., Ciani, Y., Koelzer, V. H., Tzankov, A., Haslbauer, J. D., Menter, T., Schwab, N., Henkel, M. J., Frank, A., Zsikla, V., et al. (2020) · medRxiv · doi:10.1101/2020.06.17.20133637 · Cited by 29
The Placental Protein Syncytin-1 Impairs Antiviral Responses and Exaggerates Inflammatory Responses to Influenza
Tolosa, J. M., Parsons, K. S., Hansbro, P. M., Smith, R., & Wark, P. A. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118629 · Cited by 28
High Inflammatory Burden: A Potential Cause of Myocardial Injury in Critically Ill Patients With COVID-19
Song, Y., Gao, P., Ran, T., Qian, H., Guo, F., Chang, L., Wu, W., & Zhang, S. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00128 · Cited by 28
Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system
de Queiroz, N. M. G. P., Marinho, F. V., Chagas, M., Leite, L. C. C., Homan, E. J., de Magalhães, M. T. Q., & Oliveira, S. C. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.09.004 · Cited by 27
Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19
Fouladseresht, H., Doroudchi, M., Rokhtabnak, N., Abdolrahimzadehfard, H., Roudgari, A., Sabetian, G., & Paydar, S. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.10.002 · Cited by 29
Host Immune Responses to SARS Coronavirus in Humans
Li, C. K.-F., & Xu, X. (2009) · Springer eBooks · doi:10.1007/978-3-642-03683-5_16 · Cited by 26
Human coronaviruses and therapeutic drug discovery
Song, L., Xie, Q.-X., Lao, H., & Lv, Z. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00812-9 · Cited by 28
Immune response to SARS‐CoV‐2 in children: A review of the current knowledge
Filippatos, F., Tatsi, E., & Michos, A. G. (2021) · Pediatric Investigation · doi:10.1002/ped4.12283 · Cited by 26
T Cell Epitope Specificity and Pathogenesis of Mouse Hepatitis Virus-1–Induced Disease in Susceptible and Resistant Hosts
Khanolkar, A., Fulton, R. B., Epping, L. L., Pham, N., Tifrea, D., Varga, S. M., & Harty, J. T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902749 · Cited by 26
Genetic Determinants of Mouse Hepatitis Virus Strain 1 Pneumovirulence
Leibowitz, J. L., Srinivasa, R., Williamson, S. T., Chua, M. M., Liu, M., Wu, S., Kang, H., Ma, X., Zhang, J., Shalev, I., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00330-10 · Cited by 26
Comparative Pathogenesis of Three Human and Zoonotic SARS-CoV Strains in Cynomolgus Macaques
Rockx, B., Feldmann, F., Brining, D. L., Gardner, D., LaCasse, R. A., Kercher, L. A., Long, D., Rosenke, R., Virtaneva, K. I., Sturdevant, D. E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018558 · Cited by 25
COVID-19: Integrating the Complexity of Systemic and Pulmonary Immunopathology to Identify Biomarkers for Different Outcomes
Fraga‐Silva, T. F. D. C., Maruyama, S. R., Sorgi, C. A., Russo, E. M. D. S., Fernandes, A. P., Cardoso, C. R. D. B., Faccioli, L. H., Dias‐Baruffi, M., & Bonato, V. L. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.599736 · Cited by 26
Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic’s COVID-19 registry
Sen, P., Majumdar, U., Zein, J., Hatipoglu, U. S., & Attaway, A. H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252576 · Cited by 25
Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns
Mslati, H., Gentile, F., Perez, C. F., & Cherkasov, A. R. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00384 · Cited by 29
Chemokine Regulation During Epidemic Coronavirus Infection
Majumdar, S., & Murphy, P. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.600369 · Cited by 22
Regulation of interferon production as a potential strategy for COVID-19 treatmentPreprint
Deng, X., Yu, X., & Pei, J. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2003.00751 · Cited by 26
Factors associated with delayed viral shedding in COVID-19 infected patients: A retrospective small-scale study
Cao, H., Zhu, X.-Y., Zhou, L., Zhang, H., Gu, B., Tang, W., Ding, J., Huang, J., Shen, X.-H., & Chen, C. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106328 · Cited by 24
Immunosuppressive Mechanisms During Viral Infectious Diseases
Sarikonda, G., & von Herrath, M. G. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-869-0_27 · Cited by 23
Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients—Lessons Learned From SARS and MERS
Möhn, N., Pul, R., Kleinschnitz, C., Prüß, H., Witte, T., Stangel, M., & Skripuletz, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01059 · Cited by 23
Lack of group X secreted phospholipase A2 increases survival following pandemic H1N1 influenza infection
Kelvin, A. A., Degousée, N., Banner, D., Stefanski, E., Leon, A. J., Angoulvant, D., Paquette, S. G., Huang, S. S. H., Danesh, A., Robbins, C. S., et al. (2014) · Virology · doi:10.1016/j.virol.2014.01.030 · Cited by 23
Self-citation
Pathogen screening and prognostic factors in children with severe ARDS of pulmonary origin
Phung, T. T. B., Suzuki, T., Phúc, P. H., Kawachi, S., Furuya, H., Thu, H. N., Kageyama, T., Tuan, T. A., Đao, N. H., Nunoi, H., et al. (2017) · Pediatric Pulmonology · doi:10.1002/ppul.23694 · Cited by 23
Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus
Darbeheshti, F., Mahdiannasser, M., Uhal, B. D., Ogino, S., Gupta, S., & Rezaei, N. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2234 · Cited by 23
Clinical Characterization and Possible Pathological Mechanism of Acute Myocardial Injury in COVID-19
Li, S., Wang, J., Yan, Y., Zhang, Z., Gong, W., & Nie, S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.862571 · Cited by 22
Plant Molecular Pharming and Plant-Derived Compounds towards Generation of Vaccines and Therapeutics against Coronaviruses
Venkataraman, S. (2022) · Vaccines · doi:10.3390/vaccines10111805 · Cited by 24
Characterization of antiviral T cell responses during primary and secondary challenge of laboratory cats with feline infectious peritonitis virus (FIPV)
Mustaffa-Kamal, F., Liu, H., Pedersen, N. C., & Sparger, E. E. (2019) · BMC Veterinary Research · doi:10.1186/s12917-019-1909-6 · Cited by 21
SARS-CoV-2 ORF8 accessory protein is a virulence factor
Belló-Pérez, M., Hurtado-Tamayo, J., Mykytyn, A. Z., Lamers, M. M., Requena-Platek, R., Schipper, D., Muñoz‐Santos, D., Ripoll-Gómez, J., Esteban, A., Sánchez‐Cordón, P. J., et al. (2023) · mBio · doi:10.1128/mbio.00451-23 · Cited by 21
An Impaired Inflammatory and Innate Immune Response in COVID-19
Park, S. H. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0068 · Cited by 22
Arrhythmias in patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: Incidences and implications
Guan, H., Liu, J., Ding, J., Liu, W., Yu, F., Bao, Y., Li, H., Wang, X., Zhou, Z., & Chen, Z. (2021) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2021.01.012 · Cited by 20
Cloning, expression and characterization of ferret CXCL10
Danesh, A., Seneviratne, C., Cameron, C., Banner, D., DeVries, M. E., Kelvin, A. A., Xu, L., Ran, L., Bosinger, S. E., Rowe, T., et al. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.09.018 · Cited by 20
Self-citation
Coronaviruses
McIntosh, K., & Peiris, M. J. S. (2009) · Wiley eBooks · doi:10.1128/9781555815981.ch51 · Cited by 19
An overview of the highly pathogenic H5N1 influenza virus
Yin, J., Liu, S., & Zhu, Y. (2013) · Virologica Sinica · doi:10.1007/s12250-013-3294-9 · Cited by 19
Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN- γ as a Novel Antiviral Approach Against COVID-19
Anjum, F. R., Anam, S., Abbas, G., Mahmood, M. S., Rahman, S. U., Goraya, M. U., Abdullah, R. M., Luqman, M., Ali, A., Kamran, M., et al. (2020) · Viral Immunology · doi:10.1089/vim.2020.0085 · Cited by 19
Potential Immune Indicators for Predicting the Prognosis of COVID-19 and Trauma: Similarities and Disparities
Fouladseresht, H., Talepoor, A. G., Eskandari, N., Norouzian, M., Ghezelbash, B., Beyranvand, M. R., Nejadghaderi, S. A., Carson‐Chahhoud, K., Kolahi, A., & Safiri, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.785946 · Cited by 20
Activation of cGAS‐STING by Lethal Malaria N67C Dictates Immunity and Mortality through Induction of CD11b+Ly6Chi Proinflammatory Monocytes
Du, Y., Luo, Y., Hu, Z., Lu, J., Liu, X., Xing, C., Wu, J., Duan, T., Chu, J., Wang, H. Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202103701 · Cited by 18
Dysregulation of the mevalonate pathway during SARS‐CoV‐2 infection: An in silico study
Marti, J. L. G., Wells, A. H., & Brufsky, A. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26743 · Cited by 18
Infectious Bronchitis Virus induces acute interferon-gamma production through polyclonal stimulation of chicken leukocytes
Ariaans, M. P., van de Haar, P. M., Hensen, E. J., & Vervelde, L. (2008) · Virology · doi:10.1016/j.virol.2008.11.021 · Cited by 19
The Role of Innate Immunity and Bioactive Lipid Mediators in COVID-19 and Influenza
Sahanic, S., Löffler‐Ragg, J., Tymoszuk, P., Hilbe, R., Demetz, E., Masanetz, R. K., Theurl, M., Holfeld, J., Gollmann‐Tepeköylü, C., Tzankov, A., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.688946 · Cited by 18
Nasopharyngeal Protein Biomarkers of Acute Respiratory Virus Infection
Burke, T. W., Henao, R., Soderblom, E. J., Tsalik, E. L., Thompson, J. W., McClain, M. T., Nichols, M., Nicholson, B. P., Veldman, T., Lucas, J. E., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.02.015 · Cited by 18
Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak
Har-Noy, M., & Or, R. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02363-3 · Cited by 20
Middle East Respiratory Syndrome Coronavirus Gene 5 Modulates Pathogenesis in Mice
Gutierrez-Alvarez, F. J., Wang, L., Fernández‐Delgado, R., Li, K., McCray, P. B., Perlman, S. M., Sola, I., Zúñiga, S., & Enjuanes, L. (2020) · Journal of Virology · doi:10.1128/jvi.01172-20 · Cited by 18
Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab
Menzella, F., Ghidoni, G., Galeone, C., Capobelli, S., Scelfo, C., & Facciolongo, N. C. (2021) · Biomedicines · doi:10.3390/biomedicines9040348 · Cited by 17
Immune Profiling of COVID-19 in Correlation with SARS and MERS
Khalil, B. A., Shakartalla, S. B., Goel, S., Mdkhana, B., Halwani, R., Maghazachi, A. A., AlSafar, H. S., Al‐Omari, B., & Bataineh, M. T. A. (2022) · Viruses · doi:10.3390/v14010164 · Cited by 18
Distinctive evolution of alveolar T cell responses is associated with clinical outcomes in unvaccinated patients with SARS-CoV-2 pneumonia
Markov, N. S., Ren, Z., Senkow, K. J., Grant, R. A., Gao, C. A., Malsin, E. S., Sichizya, L., Kihshen, H., Helmin, K. A., Jovisic, M., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01914-w · Cited by 19
Cytokine Storm May Not Be the Chief Culprit for the Deterioration of COVID-19
Gao, Y., Wang, C., Kang, K., Peng, Y., Luo, Y., Liu, H., Yang, W. Z., Zhao, M., & Yu, K. (2020) · Viral Immunology · doi:10.1089/vim.2020.0243 · Cited by 17
Overlapping and distinct features of viral and allergen immunity in the human lung
Harker, J. A., & Lloyd, C. M. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.010 · Cited by 18
Immunopathogenesis of 2009 pandemic influenza
Almansa, R., Bermejo-Martín, J. F., & Leonardo, R. O. D. L. (2012) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(12)70100-3 · Cited by 17
Serum levels of type I interferon (IFN-I) is associated with the severity of COVID-19
Sun, Y., Wang, G., Wang, R., Ren, L., Yuan, Z., Liu, Y., Wu, Y., Chen, R., Chen, Y., & Diao, B. (2023) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001694 · Cited by 16
Cytokine storm and translating IL-6 biology into effective treatments for COVID-19
Li, T., Wang, D., Wei, H., & Xu, X. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1044-4 · Cited by 16
Potential of algal metabolites for the development of broad‐spectrum antiviral therapeutics: Possible implications in COVID ‐19 therapy
Sangtani, R., Ghosh, A., Jha, H. C., Parmar, H. S., & Bala, K. (2020) · Phytotherapy Research · doi:10.1002/ptr.6948 · Cited by 16
Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm
Niedźwiedzka‐Rystwej, P., Majchrzak, A., Kurkowska, S., Małkowska, P., Sierawska, O., Hrynkiewicz, R., & Parczewski, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094545 · Cited by 19
Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging
Liu, Q., Zhou, S., Fan, C., Huang, W., Li, Q., Liu, S., Wu, X., Li, B., & Wang, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-03852-0 · Cited by 15
The Swine IFN System in Viral Infections: Major Advances and Translational Prospects
Razzuoli, E., Armando, F., Paolis, L. D., Ciurkiewicz, M., & Amadori, M. (2022) · Pathogens · doi:10.3390/pathogens11020175 · Cited by 15
Targeting the Complement–Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy
Trivedi, V. S., Magnusen, A. F., Rani, R., Marsili, L., Slavotinek, A. M., Prows, D. R., Hopkin, R. J., McKay, M. A., & Pandey, M. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214340 · Cited by 15
Profile of coronavirus disease enlightened asthma as a protective factor against death: An epidemiology study from Brazil during the pandemic
Sansone, N. M. S., Valencise, F. E., Bredariol, R. F., Peixoto, A. O., & Marson, F. A. L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.953084 · Cited by 17
Methotrexate inhibition of SARS-CoV-2 entry, infection and inflammation revealed by bioinformatics approach and a hamster model
Chen, Y., Chang, Y.-H., Pathak, N., Tzou, S.-C., Luo, Y.-C., Hsu, Y.-C., Li, T., Lee, J.-Y., Chen, Y.-C., Huang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1080897 · Cited by 15
Molecular Aspects of Co-morbidities in COVID-19 Infection.
Pouya, F., Saber, Z. I., & Kerachian, M. A. (2020) · PubMed Central · doi:10.22038/abjs.2020.47828.2361 · Cited by 15
Chloroquine and Hydroxychloroquine
Barber, B. E. (2017) · doi:10.1201/9781498747967-175 · Cited by 15
Microvascular Skin Manifestations Caused by COVID-19
Gawaz, A., & Guenova, E. (2021) · Hämostaseologie · doi:10.1055/a-1581-6899 · Cited by 15
Unraveling the Complexities of the Interferon Response During Sars-Cov Infection
de Lang, A., Baas, T., Smits, S. L., Katze, M. G., Osterhaus, A. D. M. E., & Haagmans, B. L. (2008) · Future Virology · doi:10.2217/17460794.4.1.71 · Cited by 15
The replication of a mouse adapted SARS-CoV in a mouse cell line stably expressing the murine SARS-CoV receptor mACE2 efficiently induces the expression of proinflammatory cytokines
Regla-Nava, J. Á., Jiménez-Guardeño, J. M., Nieto-Torres, J. L., Gallagher, T. M., Enjuanes, L., & DeDiego, M. L. (2013) · Journal of Virological Methods · doi:10.1016/j.jviromet.2013.07.039 · Cited by 15
Human coronaviruses: activation and antagonism of innate immune responses
Tanneti, N. S., Stillwell, H. A., & Weiss, S. R. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00016-23 · Cited by 14
Coronaviruses
Peiris, M. J. S. (2016) · ASM Press eBooks · doi:10.1128/9781555819439.ch52 · Cited by 13
Capillary leak syndrome: initial presentation in a patient with ALK+ anaplastic large cell lymphoma associated with increased levels of serum cytokines
Umemoto, T., Watanabe, T., Ogose, T., Kondo, R., Nakatsu, T., Sakata, A., Yamashita, M., & Gotho, T. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.555893 · Cited by 13
Systems approaches to coronavirus pathogenesis
Schäfer, A., Baric, R. S., & Ferris, M. T. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.04.007 · Cited by 13
Applications of high-throughput genomics to antiviral research: Evasion of antiviral responses and activation of inflammation during fulminant RNA virus infection
Kash, J. C. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.04.004 · Cited by 15
Comparative analyses revealed reduced spread of COVID-19 in malaria endemic countriesPreprint
Muneer, A., Kumari, K., Tripathi, M., Srivastava, R. K., Mohmmed, A., & Rathore, S. (2020) · medRxiv · doi:10.1101/2020.05.11.20097923 · Cited by 13
COVID-19 Coronavirus: Is Infection along with Mycoplasma or Other Bacteria Linked to Progression to a Lethal Outcome?
Nicolson, G. L., & Ferreira, G. (2020) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2020.115029 · Cited by 12
Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection
Ghimire, R., Shrestha, R., Amaradhi, R., Patton, T., Whitley, C., Chanda, D., Liu, L., Ganesh, T., More, S., & Channappanavar, R. (2025) · Journal of Virology · doi:10.1128/jvi.01668-24 · Cited by 13
First evidence of a pro-inflammatory response to severe infection with influenza virus H1N1
de Castro, I., Guzmán, M. G., García–Álvarez, M., & Resino, S. (2010) · Critical Care · doi:10.1186/cc8846 · Cited by 12
Severe viral pneumonia in adults: what is important for the ICU physician?
Gattarello, S., & Rello, J. (2017) · Hospital Practice · doi:10.1080/21548331.2017.1345280 · Cited by 12
Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review
Campbell, C. M., Guha, A., Haque, T. Z., Neilan, T. G., & Addison, D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092935 · Cited by 11
Clinically distinct COVID-19 cases share notably similar immune response progression: A follow-up analysis
Hausburg, M. A., Banton, K. L., Roshon, M. J., & Bar‐Or, D. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05877 · Cited by 11
Inflammatory Mechanism and Clinical Implication of Asthma in COVID-19
Wardana, V. A. W., & Rosyid, A. N. (2021) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.1177/11795484211042711 · Cited by 15
Reply to “Statins may decrease the Fatality Rate of MERS Infection”
Totura, A. L., & Baric, R. S. (2015) · mBio · doi:10.1128/mbio.01303-15 · Cited by 11
Comparative Pathogenesis of Severe Acute Respiratory Syndrome Coronaviruses
Zhang, J., Rissmann, M., Kuiken, T., & Haagmans, B. L. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052620-121224 · Cited by 10
Tuberculosis Trends in the Post‐COVID‐19 Era: Is It Going to be a Global Concern?
Khojasteh‐Kaffash, S., Habibzadeh, A., Moghaddam, S., Afra, F., Samieefar, N., & Fateh, A. (2025) · Health Science Reports · doi:10.1002/hsr2.70792 · Cited by 13
Role of cytokine storm in coronavirus infections: culprit or accomplice?
Xu, R., Liu, C., Xu, X., Hu, Y., Zhu, B., & Yang, C. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2703102 · Cited by 10
C1 esterase inhibitor-mediated immunosuppression in COVID-19: Friend or foe?
Hausburg, M. A., Williams, J. S., Banton, K. L., Mains, C. W., Roshon, M. J., & Bar‐Or, D. (2022) · Clinical Immunology Communications · doi:10.1016/j.clicom.2022.05.001 · Cited by 11
How Useful is COVID-19 Antibody Testing – A Current Assessment for Oncologists
Maple, P. A. C., & Sikora, K. (2020) · Clinical Oncology · doi:10.1016/j.clon.2020.10.008 · Cited by 10
Insights into the modulation of the interferon response and NAD+in the context of COVID-19
Habeichi, N. J., Tannous, C., Yabluchanskiy, A., Altara, R., Mericskay, M., Booz, G. W., & Zouein, F. A. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1961768 · Cited by 10
Is malaria immunity a possible protection against severe symptoms and outcomes of COVID-19?
Orish, V. N., Boakye-Yiadom, E., Ansah, E. K., Alhassan, R. K., Duedu, K. O., Awuku, Y. A., Owusu‐Agyei, S., & Gyapong, J. O. (2021) · Ghana Medical Journal · doi:10.4314/gmj.v55i2s.9 · Cited by 10
Interferon interplay helps tissue cells to cope with SARS-Coronavirus infection
Kuri, T., & Weber, F. (2010) · Virulence · doi:10.4161/viru.1.4.11465 · Cited by 9
Omalizumab may protect allergic patients against COVID-19: A systematic review
Ghiglioni, D. G., Cozzi, L., Castagnoli, R., Bruschi, G., Maffeis, L., Marchisio, P., Marseglia, G. L., & Licari, A. (2023) · World Allergy Organization Journal · doi:10.1016/j.waojou.2023.100741 · Cited by 9
Coronavirus
Franks, T. J., & Galvin, J. R. (2013) · Springer eBooks · doi:10.1007/978-3-642-40605-8_13 · Cited by 9
Cytokine profiles of suction pulmonary secretions from children infected with pandemic influenza A(H1N1) 2009
Kawashima, H., Go, S., Kashiwagi, Y., Morishima, Y., Miura, T., Ushio, M., Nishimata, S., & Takekuma, K. (2010) · Critical Care · doi:10.1186/cc8918 · Cited by 9
A narrative review on the basic and clinical aspects of the novel SARS-CoV-2, the etiologic agent of COVID-19
Hokello, J., Sharma, A. L., Shukla, G. C., & Tyagi, M. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-5272 · Cited by 9
Identification of potential vaccine targets for elicitation of host immune cells against SARS-CoV-2 by reverse vaccinology approach
Yasmin, S., Ansari, M. Y., Pandey, K., & Dikhit, M. R. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130754 · Cited by 8
Fisiopatología del daño multiorgánico en la infección por SARS-Cov2
Pérez, G. T. L., Sandoval, M. D. L. P. R., & Altamirano, M. S. T. (2020) · Acta Pediátrica de México · doi:10.18233/apm41no4s1pps27-s412042 · Cited by 8
GAPDH, Interferon γ, and Nitric Oxide: Inhibitors of Coronaviruses
Awan, A. (2021) · Frontiers in Virology · doi:10.3389/fviro.2021.682136 · Cited by 8
In silico drug repurposing to combat COVID-19 based on pharmacogenomics of patient transcriptomic data
Das, S., Camphausen, K. A., & Shankavaram, U. T. (2021) · Clinical Microbiology and Infectious Diseases · doi:10.15761/cmid.1000194 · Cited by 9
Contrasting roles of MERS-CoV and SARS-CoV-2 internal proteins in pathogenesis in mice
Wong, L.-Y. R., Odle, A. E., Luhmann, E. K., Wu, D. C., Wang, Y., Teo, Q. W., Ptak, C. C., Sariol, A., Lowery, S. A., Mack, M., et al. (2023) · mBio · doi:10.1128/mbio.02476-23 · Cited by 9
Genetic loci regulate Sarbecovirus pathogenesis: A comparison across mice and humans
Schäfer, A., Gralinski, L. E., Leist, S. R., Hampton, B. K., Mooney, M. A., Jensen, K., Graham, R. L., Agnihothram, S., Jeng, S., Chamberlin, S. R., et al. (2024) · Virus Research · doi:10.1016/j.virusres.2024.199357 · Cited by 8
The peripheral and core regions of virus-host network of COVID-19
Wang, B., Dong, X., Hu, J., Ma, X., Han, C., Wang, Y., & Gao, L. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab169 · Cited by 8
Sexually dimorphic placental responses to maternal SARS-CoV-2 infectionPreprint
Bordt, E. A., Shook, L. L., Atyeo, C. G., Pullen, K. M., Guzman, R. M. D., Meinsohn, M.-C., Chauvin, M. Y., Fischinger, S., Yockey, L. J., James, K. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.29.437516 · Cited by 8
Reviewing the insights of SARS-CoV-2: Its epidemiology, pathophysiology, and potential preventive measures in traditional medicinal system
Sharma, M., Sharma, A. K., Sharma, S., Sharma, A. K., Sharma, M., Sharma, K. K., & Sharma, M. (2024) · Clinical Traditional Medicine and Pharmacology · doi:10.1016/j.ctmp.2024.200147 · Cited by 7
Immunopathogenesis and perspectives for immunotherapy of coronavirus infection
Симбирцев, А. С. (2021) · HIV Infection and Immunosuppressive Disorders · doi:10.22328/2077-9828-2020-12-4-7-22 · Cited by 7
Distinctive and critical roles for cellular immunity and immune-inflammatory response in the immunopathology of Sendai virus infection in mice
Simon, A. Y., Sasaki, N., Ichii, O., Kajino, K., Kon, Y., & Agui, T. (2011) · Microbes and Infection · doi:10.1016/j.micinf.2011.04.003 · Cited by 7

Authors: Cameron, M. J., Ran, L., Xu, L., Danesh, A., Bermejo-Martin, J. F., Cameron, C. M., Muller, M. P., Gold, W. L., Richardson, S. E., Poutanen, S. M., Willey, B. M., DeVries, M. E., Fang, Y., Seneviratne, C., Bosinger, S. E., Persad, D., Wilkinson, P., Greller, L. D., Somogyi, R., Humar, A., Keshavjee, S., Louie, M., Loeb, M. B., Brunton, J., McGeer, A. J., the Canadian SARS Research Network, & Kelvin, D. J.
Affiliations: University Health Network (CA)
University of Valladolid, Valladolid, Spain
Mount Sinai Hospital (CA)
University of Toronto (CA)
University Health Network, Toronto, Ontario, Canada
Centre Hospitalier de l’Université de Montréal (CA)
Biosystemix, Sydenham, Ontario, Canada
Provincial Laboratory of Public Health (CA)
McMaster University (CA)
ORCID: Cameron, Mark J.
Xu, Luoling
Danesh, Ali
Cameron, Cheryl M.
Muller, Matthew P.
Gold, Wayne L.
Richardson, Susan E.
Poutanen, Susan M.
Bosinger, Steven E.
Wilkinson, Peter
Humar, Atul
Keshavjee, Shaf
Loeb, Mark B.
McGeer, Allison J.
Kelvin, David J.
Venue: Journal of Virology
Publisher: American Society for Microbiology
Published: 2007-08-15
Volume: 81
Issue: 16
Pages: 8692-8706
ISSN: 0022-538X (ISSN-L)
1098-5514
DOI: 10.1128/jvi.00527-07
PMC: PMC1951379
OpenAlex: W2049902839
Cited by: 386
References: 59
Citations by year: 2026: 2 · 2025: 7 · 2024: 8 · 2023: 14 · 2022: 31 · 2021: 71 · 2020: 121 · 2019: 5 · 2018: 1 · 2017: 8 · 2016: 7 · 2015: 10 · 2014: 11 · 2013: 10 · 2012: 10
FWCI: 6.80
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Journal of Virology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Genome Canada
Ontario Genomics
Ontario Genomics Institute
Canadian Institutes of Health Research
Topics: Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: SARS, interferon, type I interferon, interferon-stimulated genes, interferon-alpha, interferon-gamma, chemokines, innate immunity, adaptive immunity, immunopathology, SARS-CoV, spike antibodies, immunoglobulin genes, gene expression signatures, cytokine storm, H5N1 avian influenza, viral pathogenesis
MeSH terms: Adult, Aged, Aged, 80 and over, Antibodies, Viral, Antibody Formation, Female, Humans, Immunity, Innate, Interferons, Male, Middle Aged, Gene Expression, Cytokines, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Genomics, Proteomics, Severe Acute Respiratory Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks